● Recruiting
Phase II
Oncology
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
What is being tested: Telisotuzumab adizutecan (a novel targeted therapy) combined with standard chemotherapy (oxaliplatin, fluorouracil, folinic acid), bevacizumab, and panitumumab in metastatic colorectal…
09 Jul 2026
NCT06820463